نتائج البحث - Ravindranath Patel

  • يعرض 1 - 4 نتائج من 4
تنقيح النتائج
  1. 1
    Efficacy and safety of palbociclib in combination with letrozole as first-line treatment of ER-positive, HER2-negative, advanced breast cancer: expanded analyses of subgroups from the randomized pivotal trial PALOMA-1/TRIO-18

    Efficacy and safety of palbociclib in combination with letrozole as first-line treatment of ER-positive, HER2-negative, advanced breast cancer: expanded analyses of subgroups from... حسب Richard S. Finn, John Crown, Johannes Ettl, Marcus Schmidt, Igor Bondarenko, István Láng, Tamás Pintér, Katalin Boér, Ravindranath Patel, Sophia Randolph, Sindy T. Kim, Xin Huang, Patrick Schnell, Sashi Nadanaciva, Cynthia Huang Bartlett, Dennis J. Slamon

    منشور في 2016
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  2. 2
    Overall survival results from the randomized phase 2 study of palbociclib in combination with letrozole versus letrozole alone for first-line treatment of ER+/HER2− advanced breast cancer (PALOMA-1, TRIO-18)

    Overall survival results from the randomized phase 2 study of palbociclib in combination with letrozole versus letrozole alone for first-line treatment of ER+/HER2− advanced breast... حسب Richard S. Finn, Katalin Boér, Igor Bondarenko, Ravindranath Patel, Tamás Pintér, Marcus Schmidt, Yaroslav Shparyk, Anu Thummala, Олександр Войтко, Eustratios Bananis, Lynn McRoy, Keith D. Wilner, Xin Huang, Sindy Kim, Dennis J. Slamon, Johannes Ettl

    منشور في 2020
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  3. 3
    A randomized phase II trial of nab‐paclitaxel and gemcitabine with tarextumab or placebo in patients with untreated metastatic pancreatic cancer

    A randomized phase II trial of nab‐paclitaxel and gemcitabine with tarextumab or placebo in patients with untreated metastatic pancreatic cancer حسب Zishuo Ian Hu, Johanna C. Bendell, Andrea J. Bullock, Noelle K. LoConte, Hassan Hatoum, Paul S. Ritch, Hugo Hool, Joseph W. Leach, James F. Sanchez, Davendra Sohal, John H. Strickler, Ravindranath Patel, Andrea Wang‐Gillam, Irfan Firdaus, Kenneth H. Yu, Ann M. Kapoun, Eric Holmgren, Lei Zhou, Jakob Dupont, Vincent J. Picozzi, Vaibhav Sahai, Eileen M. O’Reilly

    منشور في 2019
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  4. 4
    Pathologic and molecular responses to neoadjuvant trastuzumab and/or lapatinib from a phase II randomized trial in HER2-positive breast cancer (TRIO-US B07)

    Pathologic and molecular responses to neoadjuvant trastuzumab and/or lapatinib from a phase II randomized trial in HER2-positive breast cancer (TRIO-US B07) حسب Sara A. Hurvitz, Jennifer L. Caswell‐Jin, Katherine McNamara, Jason J. Zoeller, Gregory R. Bean, Robert Dichmann, Alejandra Perez, Ravindranath Patel, Lee M. Zehngebot, Heather Allen, Linda D. Bosserman, Brian DiCarlo, April Kennedy, Armando E. Giuliano, Carmen Calfa, David Molthrop, Aruna Mani, Hsiao-Wang Chen, Judy Dering, Brad Adams, Eran Kotler, Michael F. Press, Joan S. Brugge, Christina Curtis, Dennis J. Slamon

    منشور في 2020
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:

أدوات البحث: